125 related articles for article (PubMed ID: 16317288)
1. Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
Santen RJ; Lynch AR; Neal LR; McPherson RA; Yue W
Anticancer Drugs; 2006 Jan; 17(1):33-40. PubMed ID: 16317288
[TBL] [Abstract][Full Text] [Related]
2. Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
Guan Y; Zhang Y; Xiao L; Li J; Wang JP; Chordia MD; Liu ZQ; Chung LW; Yue W; Pan D
Mol Pharm; 2017 Jan; 14(1):1-13. PubMed ID: 26992462
[TBL] [Abstract][Full Text] [Related]
3. The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Khwaja A; Sharpe CC; Noor M; Kloog Y; Hendry BM
Kidney Int; 2005 Aug; 68(2):474-86. PubMed ID: 16014024
[TBL] [Abstract][Full Text] [Related]
4. Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Yue W; Wang J; Li Y; Fan P; Santen RJ
Int J Cancer; 2005 Dec; 117(5):746-54. PubMed ID: 15957161
[TBL] [Abstract][Full Text] [Related]
5. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Erlich S; Tal-Or P; Liebling R; Blum R; Karunagaran D; Kloog Y; Pinkas-Kramarski R
Biochem Pharmacol; 2006 Aug; 72(4):427-36. PubMed ID: 16780807
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective Effect of S-trans, Trans-farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer's Disease.
Wang X; Wang Y; Zhu Y; Yan L; Zhao L
Drug Des Devel Ther; 2019; 13():4053-4063. PubMed ID: 31819374
[TBL] [Abstract][Full Text] [Related]
7. RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Jiang C; Song T; Li J; Ao F; Gong X; Lu Y; Zhang C; Chen L; Liu Y; He H; Huang O
Mol Neurobiol; 2017 Jan; 54(1):779-787. PubMed ID: 27021020
[TBL] [Abstract][Full Text] [Related]
8. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.
Ling Y; Wang X; Zhu H; Wang Z; Xu C; Wang X; Chen L; Zhang W
Arch Pharm (Weinheim); 2014 May; 347(5):327-33. PubMed ID: 24435839
[TBL] [Abstract][Full Text] [Related]
10. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
[TBL] [Abstract][Full Text] [Related]
11. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
[TBL] [Abstract][Full Text] [Related]
12. Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro.
Kraitzer A; Kloog Y; Haklai R; Zilberman M
J Pharm Sci; 2011 Jan; 100(1):133-49. PubMed ID: 20623695
[TBL] [Abstract][Full Text] [Related]
13. Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro.
Ling Y; Zhao X; Li X; Wang X; Yang Y; Wang Z; Wang X; Zhang J; Zhang Y
Cancer Chemother Pharmacol; 2015 Feb; 75(2):381-92. PubMed ID: 25542266
[TBL] [Abstract][Full Text] [Related]
14. Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities.
Ling Y; Wang Z; Wang X; Li X; Wang X; Zhang W; Dai H; Chen L; Zhang Y
Chem Biol Drug Des; 2015 Feb; 85(2):145-52. PubMed ID: 25043275
[TBL] [Abstract][Full Text] [Related]
15. Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Clarke HC; Kocher HM; Khwaja A; Kloog Y; Cook HT; Hendry BM
J Am Soc Nephrol; 2003 Apr; 14(4):848-54. PubMed ID: 12660318
[TBL] [Abstract][Full Text] [Related]
16. RAS inhibitors: potential for cancer therapeutics.
Kloog Y; Cox AD
Mol Med Today; 2000 Oct; 6(10):398-402. PubMed ID: 11006529
[TBL] [Abstract][Full Text] [Related]
17. The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Reif S; Weis B; Aeed H; Gana-Weis M; Zaidel L; Avni Y; Romanelli RG; Pinzani M; Kloog Y; Bruck R
J Hepatol; 1999 Dec; 31(6):1053-61. PubMed ID: 10604579
[TBL] [Abstract][Full Text] [Related]
18. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Weisz B; Giehl K; Gana-Weisz M; Egozi Y; Ben-Baruch G; Marciano D; Gierschik P; Kloog Y
Oncogene; 1999 Apr; 18(16):2579-88. PubMed ID: 10353601
[TBL] [Abstract][Full Text] [Related]
19. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Aizman E; Mor A; Levy A; George J; Kloog Y
Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
[TBL] [Abstract][Full Text] [Related]
20. Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Jansen B; Heere-Ress E; Schlagbauer-Wadl H; Halaschek-Wiener J; Waltering S; Moll I; Pehamberger H; Marciano D; Kloog Y; Wolff K
J Mol Med (Berl); 1999 Nov; 77(11):792-7. PubMed ID: 10619439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
